GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GRI Bio Inc (NAS:GRI) » Definitions » Cash Flow from Investing

GRI Bio (GRI Bio) Cash Flow from Investing : $-0.01 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is GRI Bio Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, GRI Bio spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, GRI Bio gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


GRI Bio Cash Flow from Investing Historical Data

The historical data trend for GRI Bio's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GRI Bio Cash Flow from Investing Chart

GRI Bio Annual Data
Trend Dec21 Dec22 Dec23
Cash Flow from Investing
- - -0.01

GRI Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.01 - - -

GRI Bio Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

GRI Bio's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

GRI Bio's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GRI Bio  (NAS:GRI) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

GRI Bio's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means GRI Bio spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

GRI Bio's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means GRI Bio gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

GRI Bio's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means GRI Bio spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

GRI Bio's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means GRI Bio gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

GRI Bio's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means GRI Bio spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

GRI Bio's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means GRI Bio gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

GRI Bio's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means GRI Bio paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

GRI Bio's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means GRI Bio paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

GRI Bio's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means GRI Bio paid $0.00 Mil for other investing activities.


GRI Bio Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of GRI Bio's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


GRI Bio (GRI Bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis.
Executives
David Leslie Szekeres director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT, SUITE 210, SAN DIEGO CA 92121
Roelof Rongen director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Camilla V Simpson director 20 ELAINE AVE., MILL VALLEY CA 94941
Albert Agro officer: Chief Medical Officer 828 RICHMOND STREET WEST, TORONTO A6 M6J 1C9
Walter Marc Hertz director, 10 percent owner, officer: Chief Executive Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Vipin Chaturvedi officer: Chief Scientific Officer 2223 AVIENDA DE LA PLAYA, SUITE 208, LA JOLLA CA 92037
Meenu Chhabra director C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Joseph E Payne director 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Leanne M. Kelly officer: Chief Financial Officer C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Marella Thorell director 1226 CHARTER LANE, AMBLER PA 19002
Arcturus Therapeutics Holdings Inc. 10 percent owner 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Penny Toren officer: SVP, Regul Affairs & Prog Mgmt C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Ofir Levi director C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Richard Ammer director, 10 percent owner C/O VALLON PHARMACEUTICALS, INC., 100 N. 18TH STREET, SUITE 300, PHILADELPHIA PA 19103
Pharma Gmbh Salmon 10 percent owner SANKT-JACOBS-STRASSE 90, CH-9002, BASEL V8 4052

GRI Bio (GRI Bio) Headlines

From GuruFocus